HSB-101
Axial Spondyloarthritis (AxSpA) & other HLA-B27-mediated conditions
PreclinicalActive
Key Facts
Indication
Axial Spondyloarthritis (AxSpA) & other HLA-B27-mediated conditions
Phase
Preclinical
Status
Active
Company
About Hillstar Bio
Hillstar Bio is a private, preclinical-stage biotech developing targeted immunotherapies designed to deplete disease-causing immune cells in autoimmune conditions. Its lead program, HSB-101, targets TRBV9+ T cells for axial spondyloarthritis (AxSpA) and is anticipated to enter Phase 1 trials in 2026. The company is backed by prominent venture capital firms and leverages a strategy of antibody engineering against validated genetic markers to de-risk development and move beyond the chronic, broad immunosuppression of current standard-of-care treatments.
View full company profile